Vanda Pharmaceuticals Inc. (VNDA) Earns Buy Rating from Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. reissued their buy rating on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a report published on Sunday. The firm currently has a $25.00 price target on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q3 2018 earnings at $0.00 EPS and Q4 2018 earnings at $0.04 EPS.
Several other research firms have also weighed in on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Thursday, October 5th. Piper Jaffray Companies increased their price target on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an overweight rating in a research report on Thursday, September 14th. Jefferies Group LLC restated a buy rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $21.50.
Vanda Pharmaceuticals (VNDA) opened at $12.95 on Friday. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. research analysts forecast that Vanda Pharmaceuticals will post -0.39 earnings per share for the current year.
A number of large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC boosted its position in Vanda Pharmaceuticals by 221.3% during the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 17,485 shares during the period. University of Notre Dame DU Lac bought a new position in Vanda Pharmaceuticals during the third quarter worth about $2,824,000. Schwab Charles Investment Management Inc. boosted its position in Vanda Pharmaceuticals by 2.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after purchasing an additional 11,647 shares during the period. Wells Fargo & Company MN boosted its position in Vanda Pharmaceuticals by 112.2% during the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after purchasing an additional 80,209 shares during the period. Finally, Cadence Capital Management LLC bought a new position in Vanda Pharmaceuticals during the third quarter worth about $1,121,000. Hedge funds and other institutional investors own 87.28% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.